MedTrace Logo

Effect of MD1003 in Amyotrophic Lateral Sclerosis

NCT03114215 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-06-04

No results posted yet for this study

Summary

This is a 6-month double blind randomized 2:1 placebo-controlled study with two arms (placebo, biotin 300 mg/day). The study will be followed by a 6-month extension phase during which all patients will receive biotin 300 mg/day.

Conditions

Interventions

DRUG

MD1003

capsules 100mg 3 times per day

DRUG

Placebo oral capsule

capsules 100mg lactose 3 times per day

Sponsors & Collaborators

  • MedDay Pharmaceuticals SA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-29
Primary Completion
2017-06-12
Completion
2017-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03114215 on ClinicalTrials.gov